Enzo Life Sciences, Inc.

Enzo Biochem, Inc.

Enzo Therapeutics, Inc.

Other

Enzo Diagnostics, Inc.

Enzo Bochem, Inc.

Enzo Therapeutics, Inc. C/o Enzo Biochem, Inc.

Enzo Life Science, Inc. C/o Enzo Biochem Inc.

Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.

Jannis G. Stavrianopoulos

Elazar Rabbani

James J. Donegan

Jack Coleman

Marleen Walner

Donegan, James J.

James J Donegan

Elazar S Rabbani

Jannis G Stavrianopoulos

Dakai Liu

Joshua Rabbani

Wayne Forrest Patton

Xiaofeng Li

Dean L Engelhardt

Jeffrey Kroll Adams

Robert Elliot Zipkin

Michael C Mullenix

Richard Jin

Wei Cheng

Robert Nussenblatt

Juan Carcamo

Yazhou Zhang

Riddhi Bhattacharyya

Dianqing (Dan) Wu

Norman E Kelker

Baoying Liu

Lai Wei

Yaron Ilan

Praveen Pande

Zaiguo Li

Yuejun Xiang

Paul Diamond

Dianqing Wu

Vincenzo Enea

Guangrong Zhang

Jayanta Roy-Chowdhury

Elazar Babbani

Norman E Keller

Jennifer June Brown

Ante Tocilj

Israel Gotsman

Richard Nussenblatt

Yuanxing Liang

Jannis G Stavrianopolous

Walner Marleen

Provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Still further provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.

Hydroxycholesterol immunoassay

Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.

Pharmaceutical compositions and methods targeting Wnt pathway proteins

The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Sphingosine pathway modulating compounds for the treatment of cancers

Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. In one embodiment, the Wnt pathway protein is the Dickkopf1 (Dkk1) protein. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, such as a Dkk1, wherein the fragment is sulfated.

Antibodies specific for sulfation sites of Wnt pathway proteins

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-&#x3b2;).

Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta

Methods for treating bone loss using sclerostin peptides

The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.

Affinity tag nucleic acid and protein compositions, and processes for using same

Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein lacking a sulfation site that is present in the native Wnt pathway protein is provided. Also provided is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.

Antibodies specific for sulfation sites of sclerostin

The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.

Immunomodulatory pharmaceutical compositions

Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.

Pharmaceutical compositions targeting WNT pathway proteins

Growing community of inventors

Long Beach, NY, United States of America

James J Donegan